Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. ("FDZJ", "the Company"), established in November 1996, is located in Zhangjiang Hi-Tech park, Pudong, Shanghai. The shareholders of the Company are well-known companies such as Shanghai Pharmaceuticals Holding Co., Ltd.,.
Bearing the idea of "the more we explore, the healthier human beings will be" in mind, aiming at the establishment of an innovative bio-pharmaceutical company with the core capacity of the intellectual properties creation, the Company is principally engaged in research, development, manufacture and sale of innovative bio-pharmaceutical products. After years of the unremitting efforts, the Company has developed new technologies and products in the fields of genetic engineering, photodynamic technology, nano technology and oral solid preparation technology which created competitive advantages. It is planned to launch new drugs gradually in future.
Depends on its preponderant capability in the bio-pharmaceutical areas, the Company has tackled many R&D projects, including "National Key Project on Development of Science and Technology", "National Plan on the Hi-tech Research and Development (Project 863)", "Key Project on Important Medicine Innovation", etc. FDZJ has been recognized as hi-tech enterprise since 1988 and authorized as "The Post-doctoral Station of Research" since 1999. In August 2002, the Company was listed on the Growth Enterprise Market ("GEM") of The Stock Exchange of Hong Kong Limited (the "Stock Exchange", Stock Code: 8231) and transferred to the Main Board of the Stock Exchange in December 2013 (Stock Code: 1349). In June 2020, the Company was listed on the STAR Market of the Shanghai Stock Exchange (Stock Code: 688505). Thus, FDZJ became one of A+H listing companies.
Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd., Shanghai Tracing Bio-technology Co., Ltd., and Fermovelty (Hongkong) Holdings Ltd. are the subsidiaries of FDZJ. The Company has rich human resource and strong technique power. About 600 high-quality employees will lead the R&D of new drugs forward for the greater progress.
| Full name | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd |
|---|---|
| Abbreviations | Fudan-Zhangjiang |
| Code | 688505 |
| Founded | 1996-11-11 |
| Listing | 2020-06-19 |
| Domicile | Shanghai |
| Website | www.fd-zj.com |
| ir@fd-zj.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Manufacturing |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 0.17 | 0.25 | 0.12 |
| R&D expenditure as a % of operating revenue | 16.70% | 12.42% | 15.41% |
| Operating Revenue | 833,802,693 | 1,029,294,769 | 741,841,425 |
| Net Income | 164,259,284 | 220,654,095 | 90,913,176 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 833.80 | 1029.29 | 741.84 |
| Operating Costs | -660.77 | -781.81 | -648.82 |
| Operating Income | 173.03 | 247.48 | 93.02 |
| Pretax Income | 176.70 | 246.31 | 93.89 |
| Income Tax | -12.44 | -25.66 | -2.98 |
| Net Income | 164.26 | 220.65 | 90.91 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 2026.57 | 1138.24 | 1020.15 |
| Non-current Assets-Total | 474.13 | 426.59 | 449.54 |
| Total Assets | 2500.70 | 1564.83 | 1469.69 |
| Liabilities | |||
| Current Liabilities-Total | 427.93 | 571.35 | 449.57 |
| Non-current Liabilities-Total | 64.29 | 60.33 | 65.69 |
| Total Liabilities | 492.21 | 631.68 | 515.26 |
| Stockholder's Equity | |||
| Share Capital | 1304.42 | 330.10 | 504.59 |
| Retained Profits | 706.51 | 601.43 | 438.63 |
| Total Owners' Equity | 2008.49 | 933.15 | 954.43 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 113.00 | 269.23 | 179.84 |
| Net Cash Flows-Investing | -46.54 | -21.14 | -48.04 |
| Net Cash Flows-Financing | 753.85 | -259.57 | -11.89 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| HKSCC NOMINEES LIMITED | 241.87（H Share） | 23.19% |
| Shanghai Pharmaceuticals Holding Co., Ltd | 139.58(A Share) | 13.38% |
| 70.56（HShare） | 6.77% | |
| China New Enterprise Investment Fund II | 156.89(A Share) | 15.04% |
| Yang Zong Meng | 80.00(A Share) | 7.67% |
| Wang Hai Bo | 57.89(A Share) | 5.55% |
| Shanghai Fudan Asset Operating Limited | 30.64(A Share) | 2.94% |
| Investco Hong Kong Limited | 26.93(H Share) | 2.58% |
| Shanghai Zhiyuan Investment Center(limited partnership) | 26.16(A Share) | 2.51% |
| Su Yong | 22.31(A Share) | 2.14% |
| Zhao Da Jun | 19.26(A Share) | 1.85% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.